CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 36 enrolled
Drug / intervention
Aspirindrug
Likely dose
Aspirin 81mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00818337
NCT00818337Phase 4Completed
CompareCT.gov

Aspirin Responsiveness in Women at Risk for Cardiac Events: A Pilot Study.

Creighton University·interventional·Posted Jan 7, 2009·Updated Dec 4, 2012

In Brief

A Phase 4 clinical trial evaluating Aspirin for Heart Disease. Completed, enrolled 36 participants across 1 site.

Detailed Summary

The objective of this pilot study is to evaluate the prevalence of biological aspirin resistance in women at risk for CHD taking low dose (81 mg) aspirin. Aspirin responsiveness will be measured with the VerifyNow device (Accumetrics; San Diego, CA). Those women identified as biologically resistant will be switched to aspirin 325 mg for 14 days and then re-tested for aspirin responsiveness.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Disease
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 7, 2009
Enrollment StartNov 1, 2008
Primary CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 17.5 years ago

Interventions

Aspirindrug

Aspirin 81mg and Aspirin 325mg, non-enteric coated, take one tablet by mouth daily